Israeli AI drug discovery company Quris has raised USD 9 million in a seed funding round led by Dr. Judith Richter and Dr. Kobi Richter, pioneers of cardiovascular intervention therapeutics. The round also saw participation from other medical leaders and strategic investors. Simultaneously, the company publicly launched its clinical-prediction AI platform.
The proceeds will be directed toward accelerating the research and development of novel therapeutics, growing its team, and entering into synergistic partnerships. The funds will also be used to test the first hundred or thousand drugs to train the AI platform.
Founded in 2019, Quris’ AI platform uses the serial organoid system or “patient-on-a-chip” technology—a small-scale simulation of the human body and organs, which is used to predict a drug’s response and effectiveness in humans. This method is believed to replace mice-testing, expedite the drug development process, and save costs significantly.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.